Home/Pipeline/Skyrizi (risankizumab)

Skyrizi (risankizumab)

Crohn's Disease (pediatric)

Phase 3Active, not recruitingNCT04995419

Key Facts

Indication
Crohn's Disease (pediatric)
Phase
Phase 3
Status
Active, not recruiting
Company

About AbbVie

AbbVie's mission is to discover and deliver transformative medicines that solve serious health issues. Its landmark achievement was building the world's top-selling drug, Humira, into a franchise while successfully navigating its patent expiry through a robust pipeline and strategic acquisitions like Allergan. The company's strategy hinges on sustained leadership in immunology, accelerated growth in oncology and neuroscience, and financial discipline to fuel high R&D investment and shareholder returns.

View full company profile

About AbbVie

AbbVie's mission is to discover and deliver transformative medicines that solve serious health issues. Its landmark achievement was building the world's top-selling drug, Humira, into a franchise while successfully navigating its patent expiry through a robust pipeline and strategic acquisitions like Allergan. The company's strategy hinges on sustained leadership in immunology, accelerated growth in oncology and neuroscience, and financial discipline to fuel high R&D investment and shareholder returns.

View full company profile